Hindi Complex Predicates: Linguistic and Computational Approaches

Complex predicates that comprise of a noun and verb e.g. yaad kar 'memory do; remember' are a productive class of multi-words in Hindi. In this thesis, we examine the challenges of identification and representation for these complex predicates in Hindi. We design and implement their representation in a lexical semantic resource as well as in lexicalized computational grammars. As productive multi-word predicates, their accurate identification is a necessity for natural language processing applications. We use a combination of linguistic and computational approaches to address these challenges. We use these methods to demonstrate the semi-automatic creation of subcategorization frames for Hindi and the development of classes for nominal predicates. Finally, we demonstrate how linguistic features and computational tools can be used in tandem to automatically identify complex predicates from unseen text

A rare case of difficulty in diagnosing sickle cell anaemia

Introduction: Sickle cell anaemia is a kind of haemolytic anaemia passed down in families. It is haemolytic anaemia caused by inheriting the sickle haemoglobin gene. Africans, as well as individuals from the Middle East, the Mediterranean region, and India's aboriginal tribes, have a lower level of the sickle haemoglobin (HbS) gene. A kind of anaemia that affects both children and adults is sickle cell anaemia. Clinical finding: For five days, patient has been experiencing generalised bodily pain and anxiety. Examining the problem: ALT (SGPT) - 97 U/L, AST (SGOT) - 56 U/L, total bilirubin - 5.4 mg percent, bilirubin conjugated - 1.7 mg percent, bilirubin unconjugated - 3.7 mg percent, total RBC count - 3.71 million/cu mm, total WBC count - 22100 cu mm, total platelets count - 6.46 lack/cu. Ultrasonography: Heterogeneous spleen. Therapeutic Intervention: Inj. Piptaz 4.5 gm TDS, Inj. Levoflox 500 mg, Tab. Hydroxyurea 500 mg, Tab. Neurobion forte, Inj. Pan 40 mg, Inj. Tramadol 100 mg. Outcome: The client's condition has improved due to the treatment. Patient no longer has generalised bodily aches, anxiety levels have decreased. Conclusion: My patient was admitted to the Medicine ward with a history of sickle cell anaemia and complaints of nonspecific body aches and anxiousness. Patient condition improved after receiving proper therapy

Image Processing Based Notice Board Reader Using Raspberry Pi

The main intention behind this paper is to reduce the “Manpower”; hence we are developing a open source audio notice software – A notice board reader with raspberry pi controls. The image processing is used in the proposed system as Image processing is the process of performing mathematical functions and operations of an image. So, this paper presents the implementation of image processing operations on Raspberry Pi. Raspberry Pi features a Broadcom system on a chip (SOC) which includes ARM compatible CPU. This platform is mainly based on python. Most of the access technology tools built for notice board they are built on the two basic building blocks of OCR software and Text-to-Speech (TTS) system. In this paper captured images are converted into the text through the use of OCR and the text files are processed by an open CV library and using E-speak command audio output is achieved

Edition 1.2 of the PARSEME Shared Task on Semi-supervised Identification of Verbal Multiword Expressions

International audienceWe present edition 1.2 of the PARSEME shared task on identification of verbal multiword expressions (VMWEs). Lessons learned from previous editions indicate that VMWEs have low ambiguity, and that the major challenge lies in identifying test instances never seen in the training data. Therefore, this edition focuses on unseen VMWEs. We have split annotated corpora so that the test corpora contain around 300 unseen VMWEs, and we provide non-annotated raw corpora to be used by complementary discovery methods. We released annotated and raw corpora in 14 languages, and this semi-supervised challenge attracted 7 teams who submitted 9 system results. This paper describes the effort of corpus creation, the task design, and the results obtained by the participating systems, especially their performance on unseen expressions

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk

Creación y Simulación de Metodologías de Análisis, Clasificación e Integración de Nuevos Requerimientos a Software Propietario

La priorización de nuevos requerimientos a implementar en un software propietario es un punto fundamental para su mantenimiento, la conservación de la calidad, observación de las reglas de negocio y los estándares de la empresa. Aunque existen herramientas de priorización basadas en técnicas probadas y reconocidas, las mismas requieren una calificación previa de cada requerimiento. Si la empresa cuenta con solicitudes provenientes de varios clientes de un mismo producto, aumentan los factores que afectan a la empresa, las herramientas disponibles no contemplan estos aspectos y hacen mucho más compleja la tarea de calificación. Este trabajo de investigación abarca la realización de un relevamiento de los métodos de priorización y selección de nuevos requerimientos utilizados por empresas de la zona de Rosario, y la definición de una metodología para la selección un nuevo requerimiento, que implica el análisis y evaluación de todas las implicaciones sobre el producto de software y la empresa, respetando sus reglas de negocio. La metodología creada conduce a la definición de los procesos para la construcción de una herramienta de calificación y priorización de nuevos requerimientos en software propietario que tiene solicitudes de varios clientes al mismo tiempo, con instrumentos de calificación que consideran todos los aspectos relacionados, proveerá técnicas de priorización actuales y emitirá informes personalizados según diferentes perspectivas de la empresa.Eje: Ingeniería de SoftwareRed de Universidades con Carreras en Informática (RedUNCI

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.

BACKGROUND: Global development goals increasingly rely on country-specific estimates for benchmarking a nation's progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 provides a comprehensive assessment of cause-specific mortality for 282 causes in 195 countries and territories from 1980 to 2017. METHODS: The causes of death database is composed of vital registration (VR), verbal autopsy (VA), registry, survey, police, and surveillance data. GBD 2017 added ten VA studies, 127 country-years of VR data, 502 cancer-registry country-years, and an additional surveillance country-year. Expansions of the GBD cause of death hierarchy resulted in 18 additional causes estimated for GBD 2017. Newly available data led to subnational estimates for five additional countries-Ethiopia, Iran, New Zealand, Norway, and Russia. Deaths assigned International Classification of Diseases (ICD) codes for non-specific, implausible, or intermediate causes of death were reassigned to underlying causes by redistribution algorithms that were incorporated into uncertainty estimation. We used statistical modelling tools developed for GBD, including the Cause of Death Ensemble model (CODEm), to generate cause fractions and cause-specific death rates for each location, year, age, and sex. Instead of using UN estimates as in previous versions, GBD 2017 independently estimated population size and fertility rate for all locations. Years of life lost (YLLs) were then calculated as the sum of each death multiplied by the standard life expectancy at each age. All rates reported here are age-standardised